Oncology and Hematology

Episodes 49-53 of 53

• 

  RestartResume

  Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs

  RestartResume

  Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs

  MinuteCE®

  Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs

  0.75 program credits

  • 

    

    Helena Yu, MD

  • 

    

    Pasi Antero Jänne, MD, PhD

  0.75 program credits

• 

  RestartResume

  Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy

  RestartResume

  Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy

  MinuteCE®

  Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy

  0.75 program credits

  • 

    

    Pasi Antero Jänne, MD, PhD

  • 

    

    Helena Yu, MD

  0.75 program credits

• 

  RestartResume

  The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer

  RestartResume

  The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer

  CME/CE

  The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer

  0.25 credits

  • 

    

    Brian Slomovitz, MD

  • 

    

    Robert L. Coleman, MD, FACOG, FACS

  0.25 credits

• 

  RestartResume

  Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers

  RestartResume

  Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers

  CME/CE Broadcast Replay

  Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers

  0.75 credits

  • 

    

    Nataliya Uboha, MD, PhD

  0.75 credits

• 

  RestartResume

  Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers  

  RestartResume

  Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers  

  CME/CE

  Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers  

  1.00 credit

  • 

    

    David H. Ilson, MD, PhD

  • 

    

    Sunnie Kim, MD

  1.00 credit